The latest deal builds on an existing collaboration between the two companies to develop ADC programmes for solid tumours. Credit: Gorodenkoff/Shutterstock.

Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services.

The partnership will leverage Samsung Biologics’ new ADC facility to support the development of a series of LigaChem’s ADC programmes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The deal builds on an existing collaboration in place between the two companies to develop ADC programmes for solid tumours.

LigaChem Biosciences president and CEO Yong-Zu Kim stated: “This collaboration with Samsung Biologics will be an important step toward strengthening the supply chain of high-quality ADC drugs and enhancing the competitiveness of both companies in the global ADC market.

“By leveraging Samsung Biologics’ extensive experience as a CDMO [contract development and manufacturing organisation], we will accelerate the development of our pipeline and quickly provide innovative ADC treatments to patients”.

Samsung Biologics’ ADC facility is a segregated suite equipped with a 500l reactor.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The facility supports the development and manufacturing process of ADC therapies, from late discovery and development to conjugation.

Samsung Biologics CEO and president John Rim stated: “The latest collaboration will further strengthen Samsung Biologics’ capabilities across all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapeutics to patients.

“We look forward to supporting our clients’ innovative ADC pipelines, ensuring the highest quality and timelines are met.”

Samsung Biologics has been investing in biotech companies through the Samsung Life Science Fund.

These investments are directed towards companies working on new ADC linker technologies, toolbox and protein engineering.

In November 2024, Samsung Biologics entered a manufacturing agreement, securing a $668m contract with a Europe-based pharmaceutical company.